Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIPCORD: Interim PSMA PET for Adaptive Radiotherapy in Metastatic Prostate Cancer
NCT07674771Phase 1Not yet recruiting
- Sponsor
- UT Southwestern Medical Center
- Start
- Oct 2026
- Primary completion
- Jun 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in prostate cancer (PCa), sponsored by UT Southwestern Medical Center. Primary endpoints: Reduction in PSMA-positive Total Tumor Volume at 1 year and Reduction in SABR treatment intensity at 1 year. Planned start Oct 2026; status: not yet recruiting.
02
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07674771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07674771.